Chief Financial Officer · ARS Pharmaceuticals, Inc. (SPRY)

Jonathan Piazza

A named executive officer of ARS Pharmaceuticals in every fiscal year CompBrief holds from FY2020 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$612,000

Salary $425,000Stock awards $0

FY2020: $6,209,273

3rd of 3 named executive officers at ARS Pharmaceuticals by FY2021 total.

3 named officers on file for ARS Pharmaceuticals, FY2021

Jonathan Piazza’s pay file — $29

  • 2 fiscal years of pay, line by line
  • SPRY’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ARS Pharmaceuticals’s whole pay program stands against its peers

  • ARS Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SPRY→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2022 (DEF 14A).

Free

Get Jonathan Piazza’s full pay file as a PDF — free

More than this page: up to 10 years of Jonathan’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jonathan Piazza compensation by year

ARS Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as ARS Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020FY2021
Salary$62,664$425,000
Bonus$100,000$0
Stock awards$0$0
Option awards$5,909,383$0
Non-equity incentive$32,226$187,000
Pension and deferred compensation$0$0
All other$105,000$0
Total$6,209,273$612,000

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ARS Pharmaceuticals, Inc. DEF 14A filed April 28, 2022, accession 0001193125-22-127830, and prior-year filings.

How this page was built: the ARS Pharmaceuticals, Inc. filed document, accession 0001193125-22-127830. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.

$6.2M
$612K
FY20
FY21
SalaryBonusNon-equity incentiveOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option56,048—$21.00

Per the Outstanding Equity Awards at Fiscal Year-End table in ARS Pharmaceuticals, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

ARS Pharmaceuticals’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Laura ShawverChief Executive Officer$821,500
Valerie OdegardPresident and Chief Scientific Officer$633,600
Jonathan Piazza · this pageChief Financial Officer$612,000

The full ARS Pharmaceuticals compensation record

free company brief

This page is one person within ARS Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ARS Pharmaceuticals proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ARS Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jonathan Piazza's compensation dossier · One-time report. No refunds.